The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
Open accessAbstract
BACKGROUND: In 2008, a national human papillomavirus (HPV) immunisation programme began in Scotland for 12-13 year old females with a three-year catch-up campaign for those under the age of 18. Since 2008, three-dose uptake of bivalent vaccine in the routine cohort aged 12-13 has exceeded 90% annually, while in the catch-up cohort overall uptake is 66%. METHODS: To monitor the impact of HPV immunisation, a programme of national surveillance was established (pre and post introduction) which included yearly sampling and HPV genotyping of women attending for cervical screening at age 20. By linking individual vaccination, screening and HPV testing records, we aim to determine the impact of the immunisation programme on circulating type-specific HPV infection particularly for four outcomes: (i) the vaccine types HPV 16 or 18 (ii) types considered to be associated with cross-protection: HPV 31, 33 or 45; (iii) all other high-risk types and (iv) any HPV. RESULTS: From a total of 4679 samples tested, we demonstrate that three doses (n=1100) of bivalent vaccine are associated with a significant reduction in prevalence of HPV 16 and 18 from 29.8% (95% confidence interval 28.3, 31.3%) to 13.6% (95% confidence interval 11.7, 15.8%). The data also suggest cross-protection against HPV 31, 33 and 45. HPV 51 and 56 emerged as the most prevalent (10.5% and 9.6%, respectively) non-vaccine high-risk types in those vaccinated, but at lower rates than HPV 16 (25.9%) in those unvaccinated. CONCLUSIONS: This data demonstrate the positive impact of bivalent vaccination on the prevalence of HPV 16, 18, 31, 33 and 45 in the target population and is encouraging for countries which have achieved high-vaccine uptake.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A review of human carcinogens—Part B: biological agents
Bouvard, V., Baan, R., Straif, K., Grosse, Y., Secretan, B., Ghissassi, F. E., Benbrahim-Tallaa, L., Guha, N., Freeman, C., Galichet, L., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70096-8 · Cited by 2,935
de Sanjose, S., Quint, W. G., Alemany, L., Geraets, D. T., Klaustermeier, J. E., Lloveras, B., Tous, S., Felix, A., Bravo, L. E., Shin, H.-R., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70230-8 · Cited by 2,728
Cited by
Drolet, M., Bénard, É., Pérez, N., Brisson, M., Ali, H., Boily, M.-C., Baldo, V., Brassard, P., Brotherton, J. M. L., Callander, D., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30298-3 · Cited by 1,384
Self-citationDrolet, M., Bénard, É., Boily, M.-C., Ali, H., Baandrup, L., Bauer, H., Beddows, S., Brisson, J., Brotherton, J. M. L., Cummings, T., et al. (2015) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)71073-4 · Cited by 642
Self-citationArbyn, M., Xu, L., Simoens, C., & Martin-Hirsch, P. P. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd009069.pub3 · Cited by 621
Prevalence of HPV After Introduction of the Vaccination Program in the United States
Markowitz, L. E., Liu, G., Hariri, S., Steinau, M., Dunne, E. F., & Unger, E. R. (2016) · Pediatrics · doi:10.1542/peds.2015-1968 · Cited by 383
Tabrizi, S. N., Brotherton, J. M. L., Kaldor, J. M., Skinner, S. R., Liu, B., Bateson, D., McNamee, K., Garefalakis, M., Phillips, S., Cummins, E., et al. (2014) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(14)70841-2 · Cited by 301
Kavanagh, K., Pollock, K. G., Cuschieri, K., Palmer, T., Cameron, R. L., Watt, C., Bhatia, R., Moore, C., Cubie, H., Cruickshank, M., et al. (2017) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(17)30468-1 · Cited by 263
Self-citationSankaranarayanan, R., Joshi, S., Muwonge, R., Esmy, P. O., Basu, P., Prabhu, P., Bhatla, N., Nene, B. M., Shaw, J., Poli, U. R. R., et al. (2018) · Vaccine · doi:10.1016/j.vaccine.2018.02.087 · Cited by 164
Whitworth, H. S., Gallagher, K. E., Howard, N., Mounier-Jack, S., Mbwanji, G., Kreimer, A. R., Basu, P., Kelly, H., Drolet, M., Brisson, M., et al. (2020) · Vaccine · doi:10.1016/j.vaccine.2019.12.017 · Cited by 118
Zhu, F., Hu, S., Hong, Y., Hu, Y., Zhang, X., Zhang, Y., Pan, Q., Zhang, W., Zhao, F., Zhang, C., et al. (2019) · Cancer Medicine · doi:10.1002/cam4.2399 · Cited by 55
Baasland, I., Romundstad, P. R., Eide, M. L., & Jonassen, C. M. (2019) · PLOS ONE · doi:10.1371/journal.pone.0210997 · Cited by 33
Chagas, B. S., Comar, M., Gurgel, A. P. A. D., Paiva, S., Seraceni, S., de Freitas, A. C., & Crovella, S. (2015) · PLOS ONE · doi:10.1371/journal.pone.0132570 · Cited by 19
Metadata
- Authors
- Kavanagh, K., Pollock, K. G. J., Potts, A., Love, J., Cuschieri, K., Cubie, H., Robertson, C., & Donaghy, M.
- Venue
- British Journal of Cancer
- Published
- 2014-04-15
- Volume
- 110
- Issue
- 11
- Pages
- 2804-2811
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2024898833
- Cited by
- 184
- References
- 2
- FWCI
- 21.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.